March 15, 2011

Switching from Calcineurin Inhibitor-based Regimens to a Belatacept-based Regimen in Renal Transplant Recipients: A Randomized Phase II Study


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

This is another study assessing the role of belatacept, a costimulatory blocker in renal transplantation. As opposed to previous studies in de novo patients, this randomized controlled trial included patients 6 to 36 months post-transplant who continued on treatment with a calcineurininbitor or were switched to belatacept. There was a greater improvement in GFR after twelve months in the patients switched to belatacept. There were more rejections in the belatacept-treated patients, but no graft losses.
Renal Transplantation